花旗发表研报指，将药明生物列为委托开发制造商(CDMO)领域首选标的之一，考虑收入增长加快及盈利能力改善，目标价由35港元上调至40港元，予“买入”评级。另外，该行将2025至27年各年收入预测分别上调2%、2%及1%，净利润预测分别上调15%、10%及11%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.